A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

Inclusion Criteria:

• Age ≥ 18 years

• Willing and able to give written informed consent

• Pathological documentation of tumor type and mutation prior to the first dose ofstudy drug(s), for applicable cohorts.

• There is no available standard systemic therapy available for the patient's tumorhistology and/or molecular biomarker profile; or standard therapy is intolerable,not effective, or not accessible; or patient has refused standard therapy

• Able to swallow oral medication

• Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1

• Adequate cardiovascular, hematological, liver, and renal function

• Willing to comply with all protocol-required visits, assessments, and procedures

Exclusion Criteria:

• Previous treatment with a RAS inhibitor

• Is currently receiving another study therapy or has participated in a study of aninvestigational agent and received study therapy within 4 weeks of the first dose ofERAS-0015

• Received prior palliative radiation within 14 days of Cycle 1, Day 1

• Have primary central nervous system (CNS) tumors

• Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinaldysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that mayaffect drug absorption

• Have any underlying medical condition, psychiatric condition, or social situationthat, in the opinion of the Investigator, would compromise study administration asper protocol or compromise the assessment of AEs

• Are pregnant or breastfeeding or expecting to conceive or father children within theprojected duration of the trial